Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594523 | 0.97 | DNM1 (0.56) | DNM1THRBTSHRCA1CA2 | |
| SCHEMBL11101061 | 0.97 | DNM1 (0.56) | DNM1THRBTSHRCA1CA2 | |
| SCHEMBL7778179 | 0.97 | DNM1 (0.56) | DNM1THRBTSHRCA1CA2 | |
| SCHEMBL6180238 | 0.97 | DNM1 (0.56) | DNM1THRBTSHRCA1CA2 | |
| SCHEMBL18240005 | 0.97 | DNM1 (0.56) | DNM1THRBTSHRCA1CA2 | |
| SCHEMBL338812 | 0.90 | ADRB2 (0.45) | DNM1THRBTSHRALDH1A1CNR1 | |
| SCHEMBL21540429 | 0.85 | DNM1 (0.47) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL17102803 | 0.85 | ADRB2 (0.41) | DNM1THRBTSHRALDH1A1CNR1 | |
| SCHEMBL28722243 | 0.84 | DNM1 (0.45) | DNM1THRBTSHRALDH1A1CNR1 | |
| SCHEMBL7591315 | 0.81 | DNM1 (0.52) | DNM1THRBTSHRALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | LAURUS LABS LIMITED (IN) | 2022-08-16 | — | — | US | claimed |
| US-20220033352-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF AN ALKOXYMETHYLENE-BENZOYLACETONITRILE | MEREO BIOPHARMA 1 LIMITED (GB) | 2022-02-03 | — | — | US | claimed |
| EP-3856712-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF AN ALKOXYMETHYLENE-BENZOYLACETONITRILE | Mereo BioPharma 1 Limited (GB) | 2021-08-04 | — | — | EP | claimed |
| CN-112805269-A | Synthetic method for preparing alkoxymethylene-benzoyl acetonitrile | 梅里奥生物制药1有限公司 | 2021-05-14 | — | — | CN | claimed |
| US-10953256-B2 | Composition comprising fluorine-containing ketone | SINOCHEM LANTIAN CO., LTD (CN) | 2021-03-23 | — | — | US | claimed |
| CN-107126660-B | Composition containing fluoroketone | 中化蓝天集团有限公司 | 2021-02-05 | — | — | CN | claimed |
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | LAURUS LABS LIMITED (IN) | 2020-12-31 | — | — | US | claimed |
| CN-111233923-A | Quaternary phosphonium salt flame retardant and synthetic method and application thereof | 上海交通大学 | 2020-06-05 | — | — | CN | claimed |
| WO-2020065325-A1 | SYNTHETIC METHODFOR THE PREPARATION OF AN ALKOXYMETHYLENE-BENZOYLACETONITRILE | MEREO BIOPHARMA 1 LIMITED (GB) | 2020-04-02 | — | — | WO | claimed |
| CN-110627052-A | Preparation method of water-soluble graphene | 天津理工大学 | 2019-12-31 | — | — | CN | claimed |
| CN-110627041-A | Preparation method of oil-soluble graphene | 天津理工大学 | 2019-12-31 | — | — | CN | claimed |
| EP-3421105-A1 | COMPOSITION COMPRISING FLUORINE-CONTAINING KETONE | Sinochem Lantian Co., Ltd. (CN) | 2019-01-02 | — | — | EP | claimed |
| US-20180244622-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Ltd. (IN) | 2018-08-30 | — | — | US | claimed |
| US-20180200553-A1 | COMPOSITION COMPRISING FLUORINE-CONTAINING KETONE | SINOCHEM LANTIAN CO., LTD (CN) | 2018-07-19 | — | — | US | claimed |
| EP-3344249-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Private Limited (IN) | 2018-07-11 | — | — | EP | claimed |
| WO-2017037672-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | LAURUS LABS PRIVATE LIMITED (IN) | 2017-03-09 | — | — | WO | claimed |
| WO-2015075749-A1 | NOVEL PROCESSES FOR THE PREPARATION OF VEMURAFENIB | LAURUS LABS PRIVATE LIMITED (IN) | 2015-05-28 | — | — | WO | claimed |
| US-7396932-B2 | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | claimed |
| CN-113710723-B | Use of functionalized alpha-angelicalactone | 汉高股份有限及两合公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-0272110-A2 | Erythromycin a derivatives and method for the preparation of the same | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | ACVR1, SLC10A2, CYP4A11 | DNM1 1059/4885THRB 2482/4885TSHR 1924/4885 |
| US-20180244622-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | F5, CYP4A11, VKORC1 | DNM1 889/4885THRB 3261/4885TSHR 1603/4885 |
| US-20220033352-A1 | SYNTHETIC METHOD FOR THE PREPARATION OF AN ALKOXYMETHYLENE-BENZOYLACETONITRILE | PAH, ALK, ACMSD | DNM1 4324/4885THRB 1556/4885TSHR 3607/4885 |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | ACVR1, SLC10A2, CYP4X1 | DNM1 691/4885THRB 3419/4885TSHR 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.